02 Jan FDA Wraps Up 2024 Handing Out Several Notable Regulatory Decisions

By Frank Vinluan, MedCity News

For many people, the end of the year is a mad rush to wrap things up before the holidays, and so it was for the FDA.

Notable regulatory decisions include the first drug approval for a prevalent chronic condition and a novel regenerative medicine approach to help trauma patients. In one case, a new drug approval comes as its developer takes on a new identity in the new year.

Here’s a look back at some highlights from a busy regulatory month: Read more…